Benzinga | Dec 21, 2021 04:54AM EST

SVB Leerink Maintains Outperform on Global Blood Therapeutics, Lowers Price Target to $53

SVB Leerink analyst Andrew Berens maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and lowers the price target from $56 to $53.